Burlingame, Feb. 24, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global cell therapy manufacturing market is estimated to be valued at US$ 3,755.4 million in 2022 and is expected to exhibit a CAGR of 15.2% during the forecast period (2022-2030).
Key Trends and Analysis of the Global Cell therapy Manufacturing Market:
Increasing number of regulatory approvals of cell therapy products is expected to drive the global cell therapy manufacturing market, over the forecast period. For instance, in August 2022, Charles River Laboratories International, Inc., a U.S.-based pharmaceutical company, announced that the company had received good manufacturing practice (GMP) certificate by European Medicines Agency (EMA) for the commercial production of allogeneic cell therapy products for distribution in Europe.
Moreover, key market players are involved in launching new products for the development and manufacturing of cell therapy, which is also expected to propel the growth of cell therapy manufacturing market, over the forecast period. On March 16, 2022, Thermo Fisher Scientific inc., an analytical laboratory instrument manufacturing company announced that it had introduced a large-volume electroporation system for large scale cell therapy development and manufacturing and also it enables the development of cell therapies to transfer more readily from clinical development to commercial manufacturing.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1728
Cell Therapy Manufacturing Market Report Coverage
| Report Coverage | Details | |||
| Base Year: | 2021 | Market Size in 2022: | US$ 3,755.4 Mn | |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 | |
| Forecast Period 2022 to 2030 CAGR: | 15.2% | 2030 Value Projection: | US$ 11,633.8 Mn | |
| Geographies covered: |
| |||
| Segments covered: |
| |||
| Companies covered: | WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., HEALIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc. | |||
| Growth Drivers: |
| |||
| Restraints & Challenges: |
| |||
Key Market Takeaways:
The global Cell therapy manufacturing market is expected to exhibit a CAGR of 15.2% during the forecast period owing to increasing investments by key players for development of advanced cell therapies. For instance, in January 2022, Cellino Biotech, Inc., an autonomous cell therapy manufacturing company, announced the completion of a Series A financing of US$ 80 million, led by the impact investment arm of Bayer AG —Leaps by Bayer— 8VC, and Humboldt Fund. New investors in the round include Felicis Ventures and others, joining existing investors The Engine and Khosla Ventures. The company has raised a total of US$ 96 million in gross proceeds from private financings.
Among Therapy Type, Allogeneic Cell Therapy segment is expected to hold a dominant position over the forecast period, owing to increasing inorganic activities such as collaboration for the development of new allogeneic therapy by key market players. For instance, on August 9, 2022, Century Therapeutics, a biotechnology company and Bristol Meyer Squibb, an American multinational pharmaceutical company, entered into a collaboration and license agreement to develop and commercialize iPSC-derived allogeneic cell therapy platform for hematologic malignancies and solid tumors. Under this agreement, Century Therapeutics will be responsible for the development and preclinical trials of cell therapy while Bristol Meyer Squibb will be responsible for the clinical development and commercialization activities.
On the basis of applications, oncology segment is expected to hold a dominant position over the forecast period, owing to expansion of manufacturing facility in order to increase the manufacturing capacity for the cancer therapies by key market players. For instance, on April 19, 2022, Kite, a subsidiary of Gilead Company received U.S. Food and Drug Administration (FDA) approval for the commercialization of the production of new CAR-T cell therapy, at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland, U.S.
Competitive Landscape:
Key players operating in the global cell therapy manufacturing market include WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., HEALIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1728
Market Segmentation:
- Global Cell Therapy Manufacturing Market, By Therapy Type:
- Allogeneic Cell Therapy
- Autologous Cell Therapy
- Global Cell Therapy Manufacturing Market, By Technology Type:
- Somatic Cell Technology
- Cell ImmortalizationTechnology
- Viral Vector Technology
- Genome Editing Technology
- Cell Plasticity Technology
- 3D Technology
- Global Cell Therapy Manufacturing Market, By Source:
- IPSC’s (Induced pluripotent stem cell)
- Bone Marrow
- Umbilical Cord
- Adipose Tissue
- Neural Stem
- Global Cell Therapy Manufacturing Market, By Application:
- Musculoskeletal
- Cardiovascular
- Gastrointestinal
- Neurological
- Oncology
- Dermatology
- Others
- Global Cell Therapy Manufacturing Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- By Region/Country
- North America
Related Market Intelligence Reports:
CAR T Cell Therapy Market, By Targeted Antigen (CD19, BCMA, HER2, GD2, CD20, CD22, CD30, CD33, HER1, Others (CLDN18, etc.)), By Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Glioblastoma, Sarcoma, Neuroblastoma, Acute Myeloid Leukemia, Breast Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Others (Gastric Cancer, etc.)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
Plasmid DNA Manufacturing Market, By Product Type (Viral Vectors, Plasmid DNA and Non-viral Vectors), By Grade (GMP Grade, R&D Grade and Clinical Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, RNA Vaccines and Others), By Manufacturing Type (Outsourcing and In-house Manufacturing), By Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics and Marketed Therapeutics), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
